Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isolated limb perfusion: the European experience.

F J Lejeune1, B B Kroon, F Di Filippo

  • 1Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ferdy.lejeune@chuv.hospvd.ch

Surgical Oncology Clinics of North America
|October 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.

Frontiers in nephrology·2025
Same author

Dual-task-related gait patterns as possible marker of precocious and subclinical cognitive alterations in Parkinson disease.

Scientific reports·2025
Same author

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.

Frontiers in nephrology·2023
Same author

Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2018
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Isolated limb perfusion (ILP) delivers high-dose cancer drugs directly to a limb, achieving high remission rates for melanoma and sarcomas. This targeted approach enables limb-sparing surgery and demonstrates effective anti-angiogenic therapy.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Pharmacology

Background:

  • Isolated limb perfusion (ILP) is a regional chemotherapy technique.
  • It allows high-dose drug delivery while isolating the limb from systemic circulation.
  • Melanoma and sarcomas are significant challenges in limb oncology.

Purpose of the Study:

  • To evaluate the efficacy of ILP with melphalan for melanoma treatment.
  • To assess ILP with tumor necrosis factor and melphalan as neoadjuvant therapy for sarcomas.
  • To demonstrate the clinical application of an anti-angiogenic regimen.

Main Methods:

  • ILP involves surgically isolating a limb and perfusing it with high-dose anticancer agents.
  • Continuous leakage monitoring is employed during perfusion.

Related Experiment Videos

  • Melanoma patients received melphalan via ILP.
  • Sarcoma patients received ILP with tumor necrosis factor and melphalan.

    • Main Results:

    • High complete remission rates were achieved in melanoma patients treated with melphalan ILP.
    • ILP with tumor necrosis factor and melphalan proved effective as neoadjuvant treatment for limb-sparing surgery in sarcoma patients.
    • The study demonstrated the first active anti-angiogenic regimen in clinical practice.

    Conclusions:

    • ILP with melphalan is effective for treating melanoma.
    • ILP with tumor necrosis factor and melphalan is a viable neoadjuvant strategy for limb sarcomas.
    • This approach represents a significant advancement in clinical anti-angiogenic therapy.